Versantis Overview
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$47.9M
- Investors
-
1
Versantis General Information
Description
Operator of a drug development company intended to develop disruptive therapies for rare liver and pediatric diseases. The company offers an innovative liposomal-based intra-peritoneal fluid that acts as a clearance enhancer for a large spectrum of toxic metabolites accumulated during decompensated liver cirrhosis and clears ammonia from the body, thereby enabling physicians to treat patients with acute liver diseases.
Contact Information
Website
www.versantis.comCorporate Office
- Technoparkstrasse 1
- 8005 Zurich
- Switzerland
Corporate Office
- Technoparkstrasse 1
- 8005 Zurich
- Switzerland
Versantis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 29-Sep-2022 | $47.9M | Completed | Generating Revenue | ||
| 12. Grant | 13-Apr-2022 | Completed | Clinical Trials - General | |||
| 11. Later Stage VC (Series B) | 18-Sep-2019 | Completed | Clinical Trials - General | |||
| 10. Early Stage VC (Series A) | 04-Apr-2017 | Completed | Clinical Trials - General | |||
| 9. Accelerator/Incubator | 19-May-2016 | Completed | Clinical Trials - General | |||
| 8. Grant | 01-Jul-2015 | Completed | Clinical Trials - General | |||
| 7. Seed Round | 01-Mar-2015 | Completed | Clinical Trials - General | |||
| 6. Grant | 13-Aug-2014 | Completed | Clinical Trials - General | |||
| 5. Grant | 01-Jul-2014 | $55.8K | $112K | Completed | Clinical Trials - General | |
| 4. Debt - General | 01-Jun-2014 | $112K | $112K | Completed | Clinical Trials - General |
Versantis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A | ||||||||
| Series A | 51,475 | $44.1 | $44.1 | 1x | $44.1 | 22.82% |
Versantis Comparisons
Industry
Financing
Details
Versantis Competitors (42)
One of Versantis’s 42 competitors is Attune Pharmaceuticals, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY | ||||
| Cellaion | Formerly VC-backed | Mont-Saint-Guibert, Belgium | ||||
| Ochre Bio | Venture Capital-Backed | Oxford, United Kingdom | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| ABIONYX Pharma | Formerly VC-backed | Balma, France |
Versantis Patents
Versantis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250339393-A1 | Use of transmembrane ph gradient liposomes for treating hyperammonemic crisis associated with inborn errors of metabolism | Pending | 16-Nov-2022 | ||
| WO-2024105101-A1 | Use of transmembrane ph gradient liposomes for treating hyperammonemic crisis associated with inborn errors of metabolism | Inactive | 16-Nov-2022 | ||
| CA-3221837-A1 | Unsaturated hydroxamic acid derivatives and their use for the treatment and prevention of an ammonia-associated disease or disorder | Pending | 29-Jun-2021 | ||
| JP-2018519370-A | Method for preparing transmembrane ph gradient vesicles | Active | 04-May-2015 | ||
| JP-6715265-B2 | Method for preparing transmembrane ph gradient vesicles | Active | 04-May-2015 | A61K9/127 |
Versantis Signals
Versantis Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Altus Capital Partners | PE/Buyout | Minority | ||
| Esperante Ventures | Corporate Venture Capital | Minority | ||
| Gebert Rüf Foundation | Accelerator/Incubator | |||
| Innosuisse | Government | |||
| Invivo Partners | Venture Capital | Minority |
Versantis FAQs
-
Where is Versantis headquartered?
Versantis is headquartered in Zurich, Switzerland.
-
What is the size of Versantis?
Versantis has 13 total employees.
-
What industry is Versantis in?
Versantis’s primary industry is Drug Discovery.
-
Is Versantis a private or public company?
Versantis is a Private company.
-
What is the current valuation of Versantis?
The current valuation of Versantis is .
-
What is Versantis’s current revenue?
The current revenue for Versantis is .
-
How much funding has Versantis raised over time?
Versantis has raised $20.9M.
-
Who are Versantis’s investors?
Altus Capital Partners, Esperante Ventures, Gebert Rüf Foundation, Innosuisse, and Invivo Partners are 5 of 16 investors who have invested in Versantis.
-
Who are Versantis’s competitors?
Attune Pharmaceuticals, Cellaion, Ochre Bio, Sarepta Therapeutics, and ABIONYX Pharma are some of the 42 competitors of Versantis.
-
When was Versantis acquired?
Versantis was acquired on 29-Sep-2022.
-
Who acquired Versantis?
Versantis was acquired by Genfit.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process